GENB · Generate Biomedicines, Inc. · Financials
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consist of its cash, cash equivalents and marketable securities on hand at September 30, 2026, together with the $30.0 million upfront payment received from Zealand in October 2026 in connection with the Zealand collaboration, it expects to have sufficient cash to fund its current operating plan into the first half of 2028.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2026-09-30 | USD 12,499,000 | 10-Q filed 2026-11-12 |
| Current operating lease liabilities | 2026-09-30 | USD 10,830,000 | 10-Q filed 2026-11-12 |
| Noncurrent finance lease liabilities | 2026-09-30 | USD 5,891,000 | 10-Q filed 2026-11-12 |
| Noncurrent operating lease liabilities | 2026-09-30 | USD 46,121,000 | 10-Q filed 2026-11-12 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 288 similar-size Biotechnology companies (of 593 listed).